Diligence memo · auto-generated · as of July 2, 2026
Sonoma Biotherapeutics, Inc.
Sonoma Biotherapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Sonoma Biotherapeutics, Inc. operates in Biotechnology, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sonoma Biotherapeutics, Inc. has raised $265M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $265M on 2021-07-26.
Most recent recorded round closed around 2021-07-26.
Valuation (modeled)modeled
Provath models Sonoma Biotherapeutics, Inc. at approximately $7.7B (range $1.2B–$14.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.82× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.9 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 98% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Affinivax, Inc., Instil Bio, Inc., Umoja Biopharma, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.